CORT CORCEPT THERAPEUTICS INC
Price Chart
Executive Summary
Corcept disclosed that the DOJ, California Department of Insurance, and named Plaintiff States have all declined to intervene in a qui tam lawsuit filed by a former employee in February 2017 regarding the sale and promotion of Korlym. The relator served an amended complaint on June 2, 2026, and the company intends to vigorously defend. This removes the risk of government-backed prosecution, significantly reducing the potential liability exposure.
Actionable Insight
The DOJ's declination to intervene is a significant de-risking event for Corcept, removing the most severe financial threat from this qui tam action. Monitor for any future developments in the relator's amended complaint, but the absence of government backing substantially weakens the plaintiff's case. The stock may re-rate higher as this overhang lifts.
Key Facts
- DOJ, California Department of Insurance, and named Plaintiff States declined to intervene in qui tam action
- Lawsuit initiated February 2017 by former employee (Relator Stephen Elliott)
- DOJ had issued a subpoena in November 2021; company responded in full
- Relator served amended complaint on June 2, 2026
- Company intends to vigorously defend against all claims
Financial Impact
No specific financial exposure disclosed; DOJ declination removes government-backed treble damages risk, which could have been material relative to $7.6B market cap
Risk Factors
- Relator may still pursue the case independently without government support
- Amended complaint could introduce new allegations or theories of liability
- Discovery costs and management distraction from ongoing litigation
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-254622 |
| Document: 0001193125-26-254622-index-headers.html | 0001193125-26-254622 |
| Document: 0001193125-26-254622-index.html | 0001193125-26-254622 |
| Document: 0001193125-26-254622.txt | 0001193125-26-254622 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
10d ago
|
Insider Cluster
| $74.77 awaiting T+1 | awaiting T+1 | — | $82.91 (+10.89%) |
|
Jun 3, 2026
11d ago
|
Insider Cluster
| $74.89 $72.62 | ▼ −3.03% | ▼ −0.43% | $82.91 (+10.71%) |
|
Jun 3, 2026
11d ago
|
Insider Cluster
| $74.89 $72.62 | ▲ +3.03% | ▲ +0.43% | $82.91 (−10.71%) |
|
Jun 3, 2026
11d ago
|
Insider Cluster
| $74.89 $72.62 | ▼ −3.03% | ▼ −0.43% | $82.91 (+10.71%) |
|
Jun 3, 2026
11d ago
|
8-K
| $72.65 $74.89 | ▲ +3.08% | ▲ +2.68% | $82.91 (+14.12%) |
|
Jun 2, 2026
12d ago
|
Insider Cluster
| $72.65 $74.89 | ▲ +3.08% | ▲ +2.68% | $82.91 (+14.12%) |
|
May 29, 2026
16d ago
|
Insider Cluster
| $70.44 $71.20 | ▲ +1.08% | ▲ +0.93% | $82.91 (+17.70%) |
|
May 29, 2026
16d ago
|
Insider Cluster
| $70.44 $71.20 | ▲ +1.08% | ▲ +0.93% | $82.91 (+17.70%) |
|
May 1, 2026
6w ago
|
Insider Cluster
| $51.42 $51.60 | ▲ +0.35% | ▲ +0.69% | $82.91 (+61.24%) |
|
Mar 20, 2026
12w ago
|
Insider Cluster
| $34.64 $33.63 | ▼ −2.92% | ▼ −4.02% | $82.91 (+139.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access